Anti-tumor mechanism and clinical efficacy of Eribulin (Halaven®), a new microtubulin inhibitor approved for treatment of metastatic breast cancer

Abstract

A review on eribulin mesylate (Halaven; Eisai), a synthetic analog of the marine natural product halichondrin B isolated from the marine sponge Halichondria okadai being interfere with microtubule dynamics, for the treatment of patients with metastatic breast cancer previously received at least two chemotherapeutic regimens or inoperable breast cancer. [on SciFinder(R)]